New Protocol: Glofitamab with R-CHOP for High-Risk DLBCL

Phase II, open-label, multicenter study [COALITION; NCT04914741]

Younger patients (≤65 years) with high-risk large B-cell lymphoma

R-CHOP (n=40) vs Pola-R-CHP (n=40) with Glofitamab, plus consolidation therapy

OR: 100%

CR: 98%

24-mo PFS: 86%

24-mo OS: 92%

Grade >=3 AEs: 58% (equal in both arms)

Grade >=3 infections: 19% overall, 15% in arm A, 23% in arm B

Cytokine release syndrome: 21% (all ≤grade 2)

Minson A,Verner E,Giri P Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study

Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025